Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CFTR Lifecycle Map-A Systems Medicine Model of CFTR Maturation to Predict Possible Active Compound Combinations.

International journal of molecular sciences - 15 Jul 2021

Vinhoven Liza, Stanke Frauke, Hafkemeyer Sylvia, Nietert Manuel Manfred

Abstract excerpt

Different causative therapeutics for CF patients have been developed. There are still no mutation-specific therapeutics for some patients, especially those with rare CFTR mutations. For this purpose, high-throughput screens have been performed which result in various candidate compounds, with mostly unclear modes of action. In order to elucidate the mechanism of action for promising candidate substances and to be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Drug Combinations

Share to Mutation

Share to Protein Interaction Maps

Source

Open in PubMed Open full text

Identifiers

PMID: 34299207
DOI: 10.3390/ijms22147590
PMCID: PMC8306775

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CFTR Lifecycle Map-A Systems Medicine Model of CFTR Maturation to Predict Possible Active Compound Combinations.PMID 34299207Read ↗

Complementary Dual Approach for In Silico Target Identification of Potential Pharmaceutical Compounds in Cystic Fibrosis.Semantic proximity Read ↗

From CFTR to a CF signalling network: a systems biology approach to study Cystic FibrosisSemantic proximity Read ↗

From CFTR to a CF signalling network: a systems biology approach to study Cystic Fibrosis.Semantic proximity Read ↗

AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.Semantic proximity Read ↗

Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.Semantic proximity Read ↗

A genomic signature approach to rescue ΔF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function.Semantic proximity Read ↗

Genomic, transcriptomic, and protein landscape profile of CFTR and cystic fibrosis.Semantic proximity Read ↗

Proteomics and Metabolomics for Cystic Fibrosis Research.Semantic proximity Read ↗

Comparative Single-Cell Transcriptomics Uncovers Shared and Distinct Molecular Signatures in Cystic Fibrosis and Primary Ciliary DyskinesiaSemantic proximity Read ↗

Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.Semantic proximity Read ↗

Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network-based Cellular Signatures drug discovery platform.Semantic proximity Read ↗

Recent Progress in CFTR Interactome Mapping and Its Importance for Cystic FibrosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.